# Domestic Environmental Exposure and Progression of ILD: An Exploratory Case-Control Study

NCT07457502

| | |
|---|---|
| **Status** | RECRUITING |
| **Sponsor** | Ville de Paris |
| **Enrollment** | 100 participants |

## Key Eligibility Criteria

### Inclusion (11)

- Patient aged over 18 years
- Patient affected by one of the following interstitial lung diseases (ILDs): Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Pneumoconioses, ILDs associated with autoimmune features, Pleuroparenchymal Fibroelastosis (PPFE), Chronic Hypersensitivity Pneumonitis (CHP) whose etiology is not primarily related to the domestic environment, Stage 4 fibrosing sarcoidosis, unclassifiable ILDs.
- ILD patient with progressive fibrosis over the past 12 months (case group)
- ILD patient with non-progressive fibrosis over the past 12 months (control group)
- Patients without reduction in the treatment of interstitial lung disease in the 12 months prior to inclusion, patients without treatment can be included

... and 6 more (see full listing online)

### Exclusion (10)

- Patient who has already received advice from a CMEI (Environmental and Occupational Medicine Consultation Center) in the past 12 months
- Patient who has recently moved into their home (less than 1 year)
- Patient living less than 6 months per year in the home to be investigated
- Patient followed in psychiatry for a severe condition
- Patient who does not speak French and is not accompanied by a person who shares their home and speaks French to act as a translator

... and 5 more (see full listing online)

## Locations (2 total)

Hôpital Paris Saint Joseph, Paris, Paris, France
Hôpital de Tenon, Paris, Paris, France



DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.